PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients

Type Article

Journal Article


S. N. Westin; Z. Ju; R. R. Broaddus; C. Krakstad; J. Li; N. Pal; K. H. Lu; R. L. Coleman; B. T. Hennessy; S. J. Klempner; H. M. Werner; H. B. Salvesen; L. C. Cantley; G. B. Mills; A. P. Myers

Year of publication



Mol Oncol








Endometrial cancer incidence is increasing, due in part to a strong association with obesity. Mutations in the phosphatidylinositol 3-kinase (PI3K) pathway, the central relay pathway of insulin signals, occur in the majority of endometrioid adenocarcinomas, the most common form of endometrial cancer. We sought to determine the impact of PI3K pathway alterations on progression free survival in a cohort of endometrioid endometrial cancers. Prognostic utility of PIK3CA, PIK3R1, and PTEN mutations, as well as PTEN protein loss by immunohistochemistry, was explored in the context of patient body mass index. Reverse-phase protein arrays were utilized to assess protein expression based on PTEN status. Among 187 endometrioid endometrial cancers, there were no statistically significant associations between PFS and PIK3CA, PIK3R1, PTEN mutation or loss. When stratified by body mass index, PTEN loss was associated with improved progression free survival (P